Lenacapavir
Lenacapavir, sold under the brand name Sunlenca, is an antiretroviral medication used to treat HIV/AIDS. It is taken by mouth or by subcutaneous injection. The most common side effects include reactions at the injection site and nausea. Lenacapavir was approved for medical use in the European Union in August 2022, in Canada in November 2022, and in the United States in December 2022. Lenacapavir is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV/AIDS. Lenacapavir works by blocking the HIV-1 viral capsid, interfering with essential steps of the virus's lifecycle. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. Medical uses Lenacapavir, in combination with other antiretrovirals, is indicated for the treatment of HIV/AIDS. It is used in heavily treatment-experienced adults with multiple drug resistance in whom current antiretroviral therapy is ineffective due to resistance, intolerance or safety considerations. History Lenacapavir is being developed by Gilead Sciences. As of 2021, it is in phase II/III clinical trials. It is being investigated as a treatment for HIV patients infected with multidrug-resistant virus and as a twice-yearly injectable for pre-exposure prophylaxis (PrEP). The safety and efficacy of lenacapavir were